MF59 adjuvant enhances antibody responses of infant baboons immunized with Haemophilus influenzae type b and Neisseria meningitidis group C oligosaccharide-CRM197 conjugate vaccine

Infection and Immunity

Volumn 65, Issue 5, 1997, Pages 1710-1715

  Granoff, Dan M ^a,b   McHugh, Yvonne E ^a   Raff, Howard V ^a   Mokatrin, Ahmad S ^a   Van Nest, Gary A ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; BABOON; BACTERIAL MENINGITIS; HAEMOPHILUS INFLUENZAE; IMMUNOGENICITY; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; VACCINATION;

EID: 0030976101     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.65.5.1710-1715.1997     Document Type: Article

References (44)

1. Adams, W. G., K. A. Deaver, S. L. Cochi, B. D. Plikaytis, E. R. Zell, C. V. Broome, and J. D. Wenger. 1993. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA 269:221-226.
2. Amir, J., M. G. Scott, M. H. Nahm, and D. M. Granoff. 1990. Bactericidal and opsonic activity of IgG1 and IgG2 anticapsular antibodies to Haemophilus influenzae type b. J. Infect. Dis. 162:163-171.
3. 197. Infect. Immun. 39:233-238.
4. Anonymous. 1996. Progress toward elimination of Haemophilus influenzae type b disease among infants and children - United States, 1987-1995. Morbid. Mortal. Weekly Rep. 45:901-906.
5. Artenstein, M. S., R. Gold, J. G. Zimmerly, F. A. Wyle, H. Schneider, and C. Harkins. 1970. Prevention of meningococcal disease by group C polysaccharide vaccine. N. Engl. J. Med. 282:417-420.
6. Burke, R. L. 1993. Current status of HSV vaccine development, p. 367-379. In B. Roizman, R. J. Whitley, and C. Lopez (ed.), The human herpesviruses. Raven Press, Ltd., New York.
7. Costantino, P., S. Viti, A. Podda, M. A. Velmonte, L. Nencioni, and R. Rappuoli. 1992. Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C. Vaccine 10:691-698.
8. Eskola, J., and H. Kayhty. 1994. Conclusions from immunogenicity studies, efficacy trials, and large-scale use of vaccines, p. 419-434. In R. W. Ellis and D. M. Granoff (ed.), Development and clinical uses of Haemophilus b conjugate vaccines. Marcel Dekker, Inc., New York.
9. Frasch, C. E. 1995. Meningococcal vaccines: past, present and future, p. 245-283. In K. Cartwright (ed.), Meningococcal disease. John Wiley & Sons Ltd., Chichester, England.
10. Granoff, D. M., B. D. Forrest, and R. Rappuoli. 1997. Meningococcal polysaccharide-protein conjugate vaccines. Int. J. Infect. Dis. 1:152-157.
11. Granoff, D. M., S. J. Holmes, R. B. Belshe, M. T. Osterholm, J. E. McHugh, and E. L. Anderson. 1994. Effect of carrier protein priming on antibody responses to Haemophilus influenzae type b conjugate vaccines in infants. JAMA 272:1116-1121.
12. Granoff, D. M., S. J. Holmes, M. T. Osterholm, J. E. McHugh, A. H. Lucas, E. L. Anderson, R. B. Belshe, J. L. Jacobs, F. Medley, and T. V. Murphy. 1993. Induction of immunologic memory in infants primed with Haemophilus influenzae type b conjugate vaccines. J. Infect. Dis. 168:663-671.
13. Granoff, D. M., S. K. Kelsey, H. A. Bijlmer, L. Van Alphen, J. Dankert, R. E. Mandrel I, F. H. Azmi, and R. J. Scholten. 1995. Antibody responses to the capsular polysaccharide of Neisseria meningitidis serogroup B in patients with meningococcal disease. Clin. Diagn. Lab. Immunol. 2:574-582.
14. Granoff, D. M., M. H. Rathore, S. J. Holmes, P. D. Granoff, and A. H. Lucas. 1993. Effect of immunity to the carrier protein on antibody responses to Haemophilus influenzae type b conjugate vaccines. Vaccine 11:S46-S51.
15. Gupta, R. K., R. Anderson, D. Cecchini, B. Rost, P. Griffin, Jr., K. Benscoter, J. Xu, L. Montanez-Ortíz, and G. R. Siber. 1996. Development of a guineapig model for potency/immunogenicity evaluation of diphtheria, tetanus acellular pertussis (DTaP) and Haemophilus influenzae type b polysaccharide conjugate vaccines. Dev. Biol. Stand. 86:283-296.
16. Kahn, J. O., F. Sinangil, J. Baenziger, N. Murcar, D. Wynne, R. L. Coleman, K. S. Steimer, C. L. Dekker, and D. Chernoff. 1994. Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2. J. Infect. Dis. 170:1288-1291.
17. Lambert, J. S., J. McNamara, S. L. Katz, T. Fenton, M. Kang, R. Livingston, E. Hawkins, J. Moye, Jr., W. Borkowsky, D. Johnson, R. Yoger, A. M. Duliege, D. Francis, A. Gershon, D. Wara, M. Levin, G. McSherry, and G. Smith. HIV recombinant envelope vaccines in HIV-infected infants and children. Submitted for publication.
18. Langenberg, A. G., R. L. Burke, S. F. Adair, R. Sekulovich, M. Tigges, C. L. Dekker, and L. Corey. 1995. A recombinant glycoprotein vaccine for Herpes simplex virus type 2: safety and immunogenicity. Ann. Intern. Med. 122:889-898.
19. Leach, A., P. A. Twumasi, S. Kumah, W. S. Banya, S. Jaffar, B. D. Forrest, D. M. Granoff, D. E. L. Butti, G. M. Carlone, L. B. Pais, C. V. Broome, and B. M. Greenwood. 1997. Induction of immunological memory in Gambian children by immunization in infancy with a group A plus group C meningococcal polysaccharide and protein-conjugate vaccine. J. Infect. Dis. 175:200-204.
20. Lieberman, J. M., S. S. Chiu, V. K. Wong, S. Partidge, S. J. Chang, C. Y. Chiu, L. L. Gheesling, G. M. Carlone, and J. I. Ward. 1996. Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children. A randomized controlled trial. JAMA 275:1499-1503.
21. Mandrell, R. E., F. H. Azmi, and D. M. Granoff. 1995. Complement-mediated bactericidal activity of human antibodies to poly α2→8 N-acetylneuraminic acid, the capsular polysaccharide of Neisseria meningitidis serogroup B. J. Infect. Dis. 172:1279-1289.
22. Martin, J. T. 1996. Enhanced immunogenicity of Chiron Biocine adjuvanted influenza vaccine in the elderly, p. 647-652. In L. E. Brown, A. W. Hampson, and R. G. Webster (ed.). Options for the control of influenza III: proceedings of the Third International Conference on Options for the Control of Influenza, Cairns, Australia. Elsevier, Amsterdam.
23. Martin, T., R. Gasparini, S. De Donate, A. Ambozaitis, J. Schwarz, P. Crovari, S. F. Adair, A. Minutello, A. Podda, and C, Dekker. 1995, Enhanced immunogenicity of Chiron Biocine adjuvanted influenza vaccine in the elderly, abstr. H52, p. 189. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
24. Milagres, L. G., S. R. Ramos, C. T. Sacchi, C. E. Melles, V. S. Vieira, H. Sato, G. S. Brito, J. C. Moraes, and C. E. Frasch. 1994. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect. Immun. 62:4419-4424.
25. 24a.Mitchell, D. K., S. J. Holmes, R. L. Burke, R. Sekulovich, M. Tripathi, M. Doyle, and A. M. Duliege. 1997. Immunogenicity of a recombinant human cytomegalovirus (CMV) gB vaccine in toddlers, abstr. 50, p. A-25. In Program and abstracts of the 6th International Cytomegalovirus Workshop 1997.
26. Murphy, T. V., K. E. White, P. Pastor, L. Gabriel, F. Medley, D. M. Granoff, and M. T. Osterholm. 1993. Declining incidence of Haemophilus influenzae type b disease since introduction of vaccination. JAMA 269:246-248.
27. Ott, G., G. L. Barchfeld, D. Chernoff, R. Radhakrishnan, P. van Hoogevest, and G. Van Nest. 1995. MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm. Biotechnol. 6:277-296.
28. Ott, G., G. L. Barchfeld, D. Chernoff, R. Radhakrishnan, P. van Hoogevest, and G. Van Nest. 1995. MF59: Design and evaluation of a safe and potent adjuvant for human vaccines, p. 277-295. In M. F. Powell and M. J. Newman (ed.). Vaccine design: the subunit and adjuvant approach. Plenum Press, New York.
29. Peelers, C. C., A. M. Tenbergen-Meekes, J. T. Pool man, M. Beurret, B. J. Zegers, and G. T. Rijkers. 1991 Effect of carrier priming on immunogenicity of saccharide-protein conjugate vaccines. Infect. Immun. 59:3504-3510.
30. Podda, A., G. Bona, G. Canciani, A. M. Pistilli, B. Contu, R. Furlan, T. Meloni, D. Stramare, L. Titone, R. Rappuoli, D. M. Granoff, and the Italian Multicenter Group for the Study of Recumbinant Acellular Pertussis Vaccine. 1995. Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. J. Pediatr. 127:238-243.
31. Podda, A., L. Nencioni, M. T. De Magistris, A. Di Tommaso, P. Bossu, S. Nuti, P. Pileri, S. Peppoloni, M. Bugnoli, P. Ruggiero, I. Marsili, A. D'Errico, A. Tagliabue, and R. Rappuoli. 1990. Metabolic, humoral, and cellular responses in adult volunteers immunized with the genetically inactivated pertussis toxin mutant PT-9K/129G. J. Exp. Med. 172:861-868.
32. Robbins, J. B., J. C. Parke, Jr., R. Schneerson, and J. K. Whisnant. 1973. Quantitative measurement of "natural" and immunization-induced Haemophilus influenzae type h capsular polysaccharide antibodies. Pediatr. Res. 7:103-110.
33. Schneerson, R., O. Barrera, A. Sutton, and J. B. Robbins. 1980. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J. Exp, Med, 152:361-376.
34. Schneerson, R., J. B. Robbins, C. Chu, A. Sutton, W. Vann, J. C. Vickers, W. T. London, B. Curfman, M. C. Hardegree, J. Shiloach, and S. C. Rastogi. 1984. Serum antibody responses of juvenile and infant rhesus monkeys injected with Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide- protein conjugates. Infect. Immun. 45:582-591.
35. Schutze, M. P., E. Deriaud, G. Przewlocki, and C. LeClerc. 1989. Carrier-induced epitopic suppression is initiated through clonal dominance. J. Immunol. 142:2635-2640.
36. Shackley, F. M., P. T. Heath, C. Flamank, J. M. MacLennan, M. Herbert, D. M. Granoff, B. D. Forrest, and E. R. Moxon. 1996. Immunogenicity and reactogenicity of a group C meningococcal conjugate vaccine in British children, abstr. 284, p. 88. In Program and Abstracts of the Infectious Diseases Society of America 34th Annual Meeting, Infectious Diseases Society of America, Alexandria, Va.
37. Siber, G. R. 1994. Pneumococcal disease: prospects for a new generation of vaccines. Science 265:1385-1387.
38. Siber, G. R., R. Anderson, M. Habafy, and R. K. Gupta. 1995. Development of a guinea pig model to assess immunogenicity of Haemophilus influenzae type b capsular polysaccharide conjugate vaccines. Vaccine 13:525-531.
39. Twumasi, P. A., Jr., S. Kumah, A. Leach, T. J. O'Dempsey, S. J. Ceesay, J. Todd, C. V. Broome, G. M. Carlone, L. B. Pais, R K. Holder, B. D. Plikaytis, and B. M. Greenwood. 1995. A trial of a group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants. J. Infect. Dis. 171:632-638.
40. Van Nest, G. A., K. S. Steimer, N. L. Haigwood, R. L. Burke, and G. Ott. 1992. Advanced adjuvant formulations for use with recombinant subunit vaccines, p. 57-62. In F. Brown, R. M. Chanock, H. S. Ginsberg, and R. A. Lerner (ed.), Vaccines 92. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.,Y.
41. Vella, P. P., and R. W. Ellis. 1991. Immunogenicity of Haemophilus influenzae type b conjugate vaccines in infant rhesus monkeys. Pediatr. Res. 29:10-13.
42. Vella, R P., J. M. Staub, J. Armstrong, K. T. Dolan, C. M. Rusk, S. Szymanski, W. E. Greer, S. Marburg, P. J. Kniskern, T. L. Schofield, R. L. Tolman, F. Hartner, S.-H. Pan, R. J. Gerety, and R. W. Ellis. 1990. Immunogenicity of a new Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) (PedvaxHIB). Pediatrics 85:668-675.
43. Wang, J. B., S. P. Adler, S. Hempfling, R. L. Burke, A. M. Duliege, S. E. Starr, and S. A. Plotkin. 1996. Mucosal antibodies to human cytomegalovirus glycoprotein B occur following both natural infection and immunization with human cytomegalovirus vaccines. J. Infect. Dis. 174:387-392.
44. Wara, D., W. Borkowsky, J. McNamara, L. Mofenson, A. M. Duliege, D. Francis, and T. Fenton. 1995. Safety of recombinant HIV-1 envelope vaccines in newborns of infected mothers - a phase I study, abstr. 1148, p. 231. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.